Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant protein COVID 19 vaccine - West China Hospital Sichuan University/WestVac Biopharma

Drug Profile

Recombinant protein COVID 19 vaccine - West China Hospital Sichuan University/WestVac Biopharma

Alternative Names: Coviccine; Recombinant COVID-19 vaccine (Sf9 cells); Recombinant SARS-CoV-2 vaccine (Sf9 Cells)

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator West China Hospital Sichuan University
  • Developer West China Hospital Sichuan University; Westvac Biopharma
  • Class COVID-19 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 24 Mar 2025 WestVac Biopharma withdrew prior to enrolment a phase I/II trial in COVID-2019 infections (Prevention, In children, In adolescents) in China (IM, Injection), as the study was not initiated (NCT05013983)
  • 30 Dec 2023 WestVac Biopharma completes a clinical trial for COVID-2019 infections (In volunteers) in China (IM) (NCT05465785)
  • 01 Nov 2023 WestVac Biopharma completes a phase III trial in COVID-2019 infections (Prevention, In adults, In the elderly) in China (IM) (NCT04904471)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top